CytoDyn Inc.
CYDYDrugs in Pipeline
8
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
PRO 140
HIV-1-infection
PRO 140 (350 mg)
HIV
Optimized Background Regimen
HIV
Leronlimab
Solid Tumor, Adult
leronlimab 700 mg
Nonalcoholic Steatohepatitis (NASH)
350 mg leronlimab
Metastatic Colorectal Cancer (mCRC)
Leronlimab (700mg)
Coronavirus Disease 2019
PRO 140 (humanized monoclonal antibody to CCR5)
HIV -1 Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PRO 140 | Phase 3 | HIV-1-infection | - | - |
PRO 140 (350 mg) | Phase 3 | HIV | - | - |
Optimized Background Regimen | Phase 3 | HIV | - | - |
Leronlimab | Phase 2 | Solid Tumor, Adult | - | - |
leronlimab 700 mg | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
350 mg leronlimab | Phase 2 | Metastatic Colorectal Cancer (mCRC) | - | - |
Leronlimab (700mg) | Phase 2 | Coronavirus Disease 2019 | - | - |
PRO 140 (humanized monoclonal antibody to CCR5) | Phase 2 | HIV -1 Infection | - | - |